Comparison of Intralesional Triamcinolone Versus Verapamil for Keloid Treatment

NCT ID: NCT06897969

Last Updated: 2025-04-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

PHASE4

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-04-01

Study Completion Date

2025-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aims to compare the efficacy of intralesional triamcinolone and verapamil in patients presenting with keloid at our local setting. The results will guide us towards better management of keloids by choosing the more appropriate treatment. Adequate treatment will reduce significant emotional and physical distress in patients. We hypothesized that mean reduction in Vancouver Scar Score is higher in triamcinolone acetonide group compared to verapamil after three months of treatment.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Keloid Scars

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Verapamil Treatment

One ml (2.5 mg) of Intralesional Verapamil Injection will be administered monthly. The injections will be administered with an insulin syringe of 27-gauge needle. Administration of the treatment medication will be continued till the keloid is flattened or TOTAL DURATION of three months.

Group Type ACTIVE_COMPARATOR

Verapamil Injection

Intervention Type DRUG

2.5 mg of intralesional Verapamil injection monthly

Triamcinolone Treatment

Intralesional Triamcinolone acetonide (40mg) will be administered monthly. The injections will be administered with an insulin syringe of 27-gauge needle. Administration of the treatment medication will be continued till the keloid is flattened or TOTAL DURATION of three months.

Group Type EXPERIMENTAL

Triamcinolone Acetonide 1 ml of 40 mg/mL suspension

Intervention Type DRUG

Monthly intralesional injection

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Triamcinolone Acetonide 1 ml of 40 mg/mL suspension

Monthly intralesional injection

Intervention Type DRUG

Verapamil Injection

2.5 mg of intralesional Verapamil injection monthly

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* size of keloid1-5 cm,
* on any site of the body,
* duration less then five years and
* baseline Vancouver scar score of more the or equal to 5

Exclusion Criteria

* Pregnant or lactating women,
* family history of keloids,
* acromegaly, and
* congestive cardiac diseases
Minimum Eligible Age

10 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Nishtar Medical University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Dr. Asma Batool

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Dr. Aliya Akhtar, FCPS

Role: STUDY_DIRECTOR

Nishtar Medical University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Nishtar Medical University & Hospital

Multan, Punjab Province, Pakistan

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Pakistan

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Dr. Asma Batool, MBBS

Role: CONTACT

923470416435

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Dr. Asma Batool, MBBS

Role: primary

0923470416435

References

Explore related publications, articles, or registry entries linked to this study.

Kuang J, An P, Li W. Comparative efficacy and safety of verapamil and triamcinolone in keloid and hypertrophic scar treatment: a meta-analysis. J Cosmet Laser Ther. 2021 Feb 17;23(1-2):26-34. doi: 10.1080/14764172.2021.1950765. Epub 2021 Jul 18.

Reference Type BACKGROUND
PMID: 34278918 (View on PubMed)

Uzair M, Butt G, Khurshid K, Pal SS. Comparison of intralesional triamcinolone and intralesional verapamil in the treatment of keloids. Our Dermatol Online. 2015;6(3):280-4.

Reference Type BACKGROUND

Saki N, Mokhtari R, Nozari F. Comparing the Efficacy of Intralesional Triamcinolone Acetonide With Verapamil in Treatment of Keloids: A Randomized Controlled Trial. Dermatol Pract Concept. 2019 Jan 31;9(1):4-9. doi: 10.5826/dpc.0901a02. eCollection 2019 Jan.

Reference Type BACKGROUND
PMID: 30775139 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

21467/NMU

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Intralesional Treatment of Keloids
NCT06729840 RECRUITING PHASE3
Ethosomal Gel Bearing Losartan 5% for Keloid Treatment
NCT05893108 NOT_YET_RECRUITING PHASE1/PHASE2